In light of several combined modality and surgical trials for testicular seminoma currently underway, we recommend further evaluation of outcomes by de novo and relapsed CS II patients. /end
How did the change in NCCN guidelines for testicular seminoma in 2012 impact outcomes? Check out our findings in the Red Journal https://t.co/Ka8nmyK0Bf @IJROBP from @harvardradonc, led by @danielbrosen and senior author @sophia_kamran @MGHCancerCenter [1/15]
Interestingly, the combined chemoRT SAKK 01/10 trial found similar results in a pre-specified post-hoc analysis--all recurrences were in the de novo cohort; but the surgical SEMS trial did not find a difference (although RFS was lower compared to historical RT series) [14/15]